Pipeline

Our focus on and deep understanding of the biology and Mechanism of Action of the CD40 Ligand have driven Eledon’s research and development of our lead product candidate tegoprubart. Extensive preclinical and clinical stage research demonstrates that tegoprubart effectively targets the CD40L pathway, which plays a central role in organ rejection. Eledon is currently conducting clinical research on the potential benefits of treatment with tegoprubart in kidney transplantation and xenotransplantation.

The company is also assessing the benefits of targeting the CD40L in patients with autoimmune and neurodegenerative diseases including ALS. Eledon has successfully completed a Phase 2, dose ranging, biomarker study in ALS.

Indications	Preclinical	Phase 1*	Phase 2	Phase 3	Notes
Kidney Transplantation					Phase 2 BESTOW and ex-US Phase 1b enrolling Subcutaneous formulation successfully completed non-human primate study
Islet Cell Transplantation					Investigator sponsored trial at University of Chicago
Liver Transplantation					Academic collaboration
Kidney Xenotransplantation					Performed under U.S. FDA Expanded Access Protocol (EAP)
Cardiac Xenotransplantation					Performed under U.S. FDA Expanded Access Protocol (EAP)
Amyotrophic Lateral Sclerosis (ALS)					Seeking non-equity dilutive financing to advance program to Phase 3

Kidney Transplantation
Preclinical	Phase 1*	Phase 2	Phase 3	Notes
Phase 2 BESTOW and ex-US Phase 1b enrolling Subcutaneous formulation successfully completed non-human primate study
Islet Cell Transplantation
Preclinical	Phase 1*	Phase 2	Phase 3	Notes
Investigator sponsored trial at University of Chicago
Liver Transplantation
Preclinical	Phase 1*	Phase 2	Phase 3	Notes
Academic collaboration
Kidney Xenotransplantation
Preclinical	Phase 1*	Phase 2	Phase 3	Notes
Performed under U.S. FDA Expanded Access Protocol (EAP)
Cardiac Xenotransplantation
Preclinical	Phase 1*	Phase 2	Phase 3	Notes
Performed under U.S. FDA Expanded Access Protocol (EAP)
Amyotrophic Lateral Sclerosis (ALS)
Preclinical	Phase 1*	Phase 2	Phase 3	Notes
Seeking non-equity dilutive financing to advance program to Phase 3

*Including early human trials
Note: As of August, 2024. Development plans and timelines may change, including based on US and global regulatory interactions.